Ensaios Clínicos com Recrutamento Encerrado

  • Ensaios clínicos na área da diabetes tipo II

    • Ensaio clínico Carolina

    “A multicentre, international, randomised, parallel group, double blind study to evaluate cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. The CAROLINA Trial.”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013157-15/PT 

    • Ensaio clínico C-SCADE

    “A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk.”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016178-33/PT   

    • Ensaio clínico BIAsp-3963

    “A 24 week randomised, open label, 3 parallel-group comparison of once and twice daily biphasic insulin aspart (BIAsp) 30 plus sitagliptin and twice daily BIAsp 30, all in combination with metformin in insulin naïve type 2 diabetic subjects inadequately controlled on sitagliptin and metformin”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004930-33/PT 

    • Ensaio clínico SUSTAIN 

    “Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004827-19/PT  

    • Carmelina

    “A Phase 4 multicenter, randomized, double blind, placebo-controlled study to investigate the impact of long-term treatment with linagliptin on cardiovascular (CV) outcomes in a selected population of patients with type 2 diabetes mellitus and high CV risk.”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004148-23/PL

  • Ensaios clínicos na área da hepatite C

    • Ensaio clínico 1220.30

    “A Phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-a and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C infection”

    Para mais informações: 

    • Ensaio clínico 1220.48

    “A Phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-a (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN / RBV treatment”

    Para mais informações: 

  • Ensaios clínicos na área da insuficiência cardíaca

    • Ensaio clínico BAY94-8862/14564

    “Phase IIb safety and efficacy study of different oral doses of BAY 94-8862 in subjects with worsening chronic heart failure and left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone”

    Para mais informações:

  • Ensaios clínicos na área das perturbações do humor

    • Ensaio clínico CL3-20098-073

    “Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering major depressive disorder. 
    A 3-week, randomised, double then single-blind, controlled, parallel groups, international, multicentre safety study with a 5-week open extension period.”

    Para mais informações: 

    • Ensaio clínico CL3-20098-062

    Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with major depressive disorder. A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.

    Para mais informações:

    • Ensaio clínico RUBY

    “A randomized, 6-week, multicentre, open-label, rater-blinded parallel group study comparing Quetiapine extended release monotherapy and augmentation with lithium augmentation in patients with treatment resistant depression” 

    Para mais informações: 

  • Ensaios clínicos na área do carcinoma da mama

    • Ensaio clínico Neratinib

    “A Phase 3, randomized, open-label, two-arm study of neratinib plus paclitaxel Versus trastuzumab plus paclitaxel as first-line treatment for ErbB-2-positive locally recurrent or metastatic breast cancer”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007803-10/PT 

    • Ensaio clínico D-CARE

    “A randomized, double-blind, placebo-controlled, multi-center Phase 3 study of denosumab as adjuvant treatment for women with early-stage breast cancer at high risk of recurrence”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011299-32/PT 

    • Ensaio Clínico MK8669-064

    "A Phase 2 randomized trial of the combination of ridaforolimus and exemestane, compared to ridaforolimus, dalotuzumab and exemestane in high proliferation, estrogen receptor positive breast cancer patients"

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000335-11/PT  

    • Ensaio clínico MO28048 (SafeHer)

    “A phase III prospective, two-cohort non-randomized, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer [SafeHer study]”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005328-17/PT

    • Ensaio clínico MO28231

    “A multicenter, single arm study of trastuzumab emtansine (T-DM1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti-HER2 and chemotherapy-based treatment”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001628-37/PT

    • Ensaio clínico MO28047 (PerUse)

    “A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent) breast cancer”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005334-20/PT

    • Ensaio clínico NSABP FB-7

    “A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer: NSABP FB-7”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004391-35/PT

    • Ensaio clínico SOLTI-1007

    “A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000394-23/PT

    • Ensaio clínico ABI-007-MBC-001

    “A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly nab®-Paclitaxel in Combination with Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin as First Line Treatment in Subjects with ER, PgR, AND HER2 Negative (Triple Negative) Metastatic Breast Cancer”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000113-20/PT

    • Ensaio clínico MO28230

    “Phase I study of the combination of trastuzumab emtansine (T-DM1) and capecitabine in HER2-positive metastatic breast cancer and HER2-positive locally advanced/metastatic gastric cancer patients, followed by a randomized, open-label phase II study of trastuzumab emtansine and capecitabine versus trastuzumab emtansine alone in HER2-positive metastatic breast cancer”.

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001547-46/PT


    A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001931-36/PT

    • Ensaio clínico MANTA

    A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor Positive Advanced or Metastatic Breast Cancer.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002403-34/PT

    • Ensaio Clínico METAPHER

    A multicenter, open-label, single-arm safety study of Herceptin® SC in combination with PERJETA® and docetaxel in treatment of patients with her2-positive advanced breast cancer (metastatic or locally recurrent). 

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001458-40/PT

  • Ensaios clínicos na área do carcinoma da próstata

    • Ensaio clínico Millennium C21004 

    “A Phase 3, randomized, double-blind, multicenter trial comparing Orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer”

    Para mais informações: 

    • Ensaio clínico Millennium C21005 – Recrutamento encerrado

    A Phase 3, randomized, double-blind, multicenter trial comparing orteronel (TAK 700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or following docetaxel-based therapy

    Para mais informações: 

    • Ensaio clínico 212082PCR3011

    “A Study of ZYTIGA and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic Prostate Cancer”

    Para mais informações:

  • Ensaios clínicos na área do carcinoma da tiroide

    • Ensaio clínico E7080-G000-303

    “A multicenter, randomized, double-blind, placebo-controlled, Phase 3 trial of E7080 in 131I- refractory differentiated thyroid cancer”

    Para mais informações: 

  • Ensaios clínicos na área do carcinoma das células renais

    • Ensaio clínico XL184-308

    “A study evaluating cabozantinib (XL184) versus everolimus in patients with a form of kidney cancer that has progressed after treatment with another therapy”

    Para mais inrormações:

  • Ensaios clínicos na área do carcinoma do ovário

    • Ensaio clínico Trinova

    “A Phase 3, randomized, double-blind trial of weekly paclitaxel plus AMG 386 or placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or Fallopian tube cancers”

    Para mais informações:

    • Ensaio clínico LumeOvar

    “Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer”

    Para mais informações: 

  • Ensaios clínicos na área do carcinoma do pulmão

    • Ensaio clínico NEPTUNE

    A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002197-21/PT

  • Ensaios clínicos na área do carcinoma do pâncreas

    • Ensaio clínico APACT

    “A Phase 3, multicenter, open-label, randomized study of nab-paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma.”

    Para mais informações:

  • Ensaios clínicos na área do tromboembolismo venoso

    • Ensaio clínico CATCH

    “Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT”

    Para mais informações: